Malawi vs Singapore: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Malawi
91.0%
in 2025
Singapore
91.0%
in 2025
Malawi rank
59th
Singapore rank
59th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Malawi
- Singapore
How they compare
Malawi currently reports 91.0% against 91.0% in Singapore, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Singapore ahead.
Malawi ranks 59th and Singapore ranks 59th of 192 countries.
Across the 3 decades both report, Malawi averaged higher in 2 and Singapore in 1.
Head to head by decade
| Decade | Malawi | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 8.5% | 8.5% | Singapore |
| 2010s | 72.1% | 64.6% | 7.5% | Malawi |
| 2020s | 91.2% | 90.0% | 1.2% | Malawi |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Malawi or Singapore?
- Malawi, at 91.0% against 91.0% in Singapore as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Malawi and Singapore?
- 0.0%, with Malawi ahead.
- How many years of comparable data are there for Malawi and Singapore?
- 18 years are reported by both, from 2008 to 2025.
- How do Malawi and Singapore rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Malawi ranks 59th and Singapore ranks 59th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.